Holen Sie sich die Stockscreener-App
6.08
0.50%
0.03
Vorhandelsmarkt:
6.04
-0.04
-0.66%
Verastem Inc Aktie (VSTM) Neueste Nachrichten
Verastem Inc (VSTM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Verastem Inc (VSTM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Verastem Inc (VSTM) Balance Sheet - TradingKey
Verastem Inc (VSTM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Verastem Inc (VSTM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Verastem Inc (VSTM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TradingKey - TradingKey
VSTM|Verastem Inc|Price:6.085|Chg%:+0.035 - TradingKey
Verastem Inc (VSTM) Cash Flow - TradingKey
Verastem Inc (VSTM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Verastem, Inc. Revenue Breakdown – HAM:2VSA - TradingView
VSTM|Verastem Inc|Price:6.050|Chg%:-0.130 - TradingKey
Verastem Inc. (VSTM) holder outlines potential sale of 31,924 common shares - Stock Titan
Verastem Oncology to report Q2 2026 results on Aug 6 - scanx.trade
Press Release: Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026 - Moomoo
Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026 - Business Wire
Verastem Oncology to report Q2 2026 financial results in conference call - Bitget
Verastem (VSTM) Launches TARGET-D 202 Trial for KRAS G12D Lung C - GuruFocus
Phase 2 clinical trial for KRAS G12D-mutated lung cancer treatment begins at Verastem, Inc. - Traders Union
Verastem doses first patient in lung cancer trial for VS-7375 - Investing.com Canada
Verastem's Phase 2 trial targets KRAS G12D, with no FDA-approved therapy - Stock Titan
Verastem Inc (VSTM) Q1 2026 Earnings ReportResults, Call & Slides - TipRanks
These 7 Small Caps Are on Fire as the Second Half Begins: Here’s Why - Sahm
Verastem Inc. (VSTM) Posts Modest Gain as Biotech Sector Sees Renewed InterestIPO Entry Watch - dars.gov.et
Verastem’s KRAS G12D Trial Targets a New Niche in Colorectal Cancer - TipRanks
RBC Capital Reaffirms Outperform Rating For Verastem (VSTM) - Yahoo Finance
Polar Capital Holdings Plc Reduces Stake in Verastem Inc: A Stra - GuruFocus
Trading the Move, Not the Narrative: (VSTM) Edition - Stock Traders Daily
Verastem Inc. (VSTM) Q1 2026 Earnings: Narrower-Than-Expected Loss Supports Investor SentimentOne-Time Gain Impact - DonanımHaber
Verastem (VSTM) Surges 6.3%: Is This an Indication of Further Gains? - Yahoo Finance
Verastem Inc. (VSTM) Dips 5% as Biotech Volatility Persists – Technical Levels in FocusAndrews Pitchfork - dars.gov.et
Polar Capital group files 13G/A reporting 3.7M shares in Verastem (VSTM) - Stock Titan
Verastem Inc outlines oncology focus as investors weigh long-term prospects - ad-hoc-news.de
RBC Capital Maintains Verastem(VSTM.US) With Buy Rating, Cuts Target Price to $14 - Moomoo
RBC Capital Adjusts Verastem Price Target to $14 From $15, Maintains Outperform Rating - marketscreener.com
Here’s What RBC Capital Has to Say About Verastem (VSTM) - Insider Monkey
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
(VSTM) Volatility Zones as Tactical Triggers - Stock Traders Daily
VSTM Maintained by BTIG -- Price Target Unchanged at $18.00 - GuruFocus
Verastem Price Target Maintained With a $18.00/Share by BTIG - Moomoo
Verastem Oncology grants inducement awards to 31 new employees - scanx.trade
Enterprise value to EBIT forward of Verastem, Inc. – NASDAQ:VSTM - TradingView
Verastem (VSTM) Shares Encouraging Results from VS-7375 Phase 1/2 Trial - Insider Monkey
5 Best Stocks Under $10 Offering More Than 50% Upside - Insider Monkey
Verastem, Inc.(NasdaqCM: VSTM) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Verastem Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Verastem, Inc.(NasdaqCM: VSTM) dropped from Russell 3000 Value Benchmark - marketscreener.com
Verastem, Inc.(NasdaqCM: VSTM) dropped from Russell 2000 Value Benchmark - marketscreener.com
Verastem, Inc.(NasdaqCM: VSTM) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Why Did Verastem Stock Jump After-Hours Despite An Earnings Miss? - Stocktwits
Verastem, Inc. Actuals & Estimates (SWB:2VSA) - TradingView
Verastem, Inc. Stock Hits New 52-Week Low at $3.43 - MarketsMojo
Verastem, Inc. Actuals & Estimates (NASDAQ:VSTM) - TradingView
Price to earnings forward of Verastem, Inc. – NASDAQ:VSTM - TradingView
VSTM Forecast — Price Target — Prediction for 2027 - TradingView
VSTM Technical Analysis & Stock Price Forecast - Intellectia AI
Price to book forward of Verastem, Inc. – NASDAQ:VSTM - TradingView
Verastem (VSTM) insider sale notice: 21,492 shares reported for resale - Stock Titan
Verastem, Inc. Actuals & Estimates (GETTEX:2VSA) - TradingView
Enterprise value to revenue forward of Verastem, Inc. – GETTEX:2VSA - TradingView
2VSA Forecast — Price Target — Prediction for 2027 - TradingView
Is Verastem, Inc. (VSTM)’s KRAS-Targeted Combination Therapy a Breakthrough for Pancreatic Cancer? - Insider Monkey
A Quick Look at Today's Ratings for Verastem(VSTM.US), With a Forecast Between $14 to $18 - Moomoo
Price to sales forward of Verastem, Inc. – GETTEX:2VSA - TradingView
Price to book forward of Verastem, Inc. – GETTEX:2VSA - TradingView
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):